Dianthus Therapeutics (NASDAQ:DNTH) Shares Gap Up After Analyst Upgrade

Dianthus Therapeutics, Inc. (NASDAQ:DNTH)’s share price gapped up before the market opened on Thursday after Raymond James raised their price target on the stock from $34.00 to $51.00. The stock had previously closed at $23.34, but opened at $24.36. Raymond James currently has an outperform rating on the stock. Dianthus Therapeutics shares last traded at $23.94, with a volume of 9,679 shares.

A number of other analysts have also weighed in on the company. Jefferies Financial Group raised their target price on Dianthus Therapeutics from $22.00 to $39.00 and gave the company a “buy” rating in a research note on Friday, March 22nd. Stifel Nicolaus assumed coverage on Dianthus Therapeutics in a research note on Thursday, February 15th. They issued a “buy” rating and a $44.00 target price for the company. Finally, Wedbush raised their target price on Dianthus Therapeutics from $24.00 to $33.00 and gave the company an “outperform” rating in a research note on Friday, March 22nd. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $42.40.

Institutional Trading of Dianthus Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Tower Research Capital LLC TRC acquired a new stake in Dianthus Therapeutics in the fourth quarter worth about $25,000. Citigroup Inc. bought a new position in Dianthus Therapeutics during the third quarter worth about $53,000. Dimensional Fund Advisors LP bought a new position in Dianthus Therapeutics during the fourth quarter worth about $153,000. Northern Trust Corp bought a new position in Dianthus Therapeutics during the fourth quarter worth about $159,000. Finally, Acadian Asset Management LLC bought a new position in Dianthus Therapeutics during the third quarter worth about $303,000. 47.53% of the stock is currently owned by institutional investors and hedge funds.

Dianthus Therapeutics Trading Down 1.6 %

The stock has a fifty day simple moving average of $25.81 and a 200-day simple moving average of $17.23.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its earnings results on Thursday, March 21st. The company reported ($0.71) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.11) by $0.40. The company had revenue of $0.46 million for the quarter, compared to the consensus estimate of $0.73 million. On average, sell-side analysts expect that Dianthus Therapeutics, Inc. will post -1.92 EPS for the current year.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.